| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
OncoSec Medical Incorporated (NASDAQ: ONCS)
ONCS Technical Analysis
5
| As on 9th Jun 2023 ONCS STOCK Price closed @ 0.42 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.99 & Strong Sell for SHORT-TERM with Stoploss of 0.92 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ONCSSTOCK Price
| Open | 0.42 | Change | Price | % |
| High | 0.45 | 1 Day | -0.01 | -2.33 |
| Low | 0.41 | 1 Week | -0.05 | -10.64 |
| Close | 0.42 | 1 Month | -0.46 | -52.27 |
| Volume | 103638 | 1 Year | -0.72 | -63.16 |
| 52 Week High 5.94 | 52 Week Low 0.36 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ONCS Daily Charts |
ONCS Intraday Charts |
Whats New @ Bazaartrend |
ONCS Free Analysis |
|
|
ONCS Important Levels Intraday
| RESISTANCE | 0.50 |
| RESISTANCE | 0.47 |
| RESISTANCE | 0.46 |
| RESISTANCE | 0.44 |
| SUPPORT | 0.40 |
| SUPPORT | 0.38 |
| SUPPORT | 0.37 |
| SUPPORT | 0.34 |
ONCS Forecast April 2024
| 4th UP Forecast | 1.13 |
| 3rd UP Forecast | 0.9 |
| 2nd UP Forecast | 0.76 |
| 1st UP Forecast | 0.62 |
| 1st DOWN Forecast | 0.22 |
| 2nd DOWN Forecast | 0.08 |
| 3rd DOWN Forecast | -0.06 |
| 4th DOWN Forecast | -0.29 |
ONCS Weekly Forecast
| 4th UP Forecast | 0.92 |
| 3rd UP Forecast | 0.76 |
| 2nd UP Forecast | 0.66 |
| 1st UP Forecast | 0.56 |
| 1st DOWN Forecast | 0.28 |
| 2nd DOWN Forecast | 0.18 |
| 3rd DOWN Forecast | 0.08 |
| 4th DOWN Forecast | -0.08 |
ONCS Forecast2024
| 4th UP Forecast | 15.43 |
| 3rd UP Forecast | 10.62 |
| 2nd UP Forecast | 7.64 |
| 1st UP Forecast | 4.67 |
| 1st DOWN Forecast | -3.83 |
| 2nd DOWN Forecast | -6.8 |
| 3rd DOWN Forecast | -9.78 |
| 4th DOWN Forecast | -14.59 |
OncoSec Medical Incorporated ( NASDAQ USA Symbol : ONCS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ONCS Business Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey. Address: 24 North Main Street, Pennington, NJ, United States, 08534
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service